Contents shortcut Main menu shortcut
Life at CNU

The CNU Immunotherapy Innovation Center Selected for Bio-Medical Technology Development Project

작성자대외협력과 작성일2020.07.01 09:36 조회57

CNU announced that it was finally selected as the lead research institute for the 2020 Immune Therapy Innovation Platform Construction Project in the field of bio R&D technology development at the Ministry of Science and ICT.
 
This project, which was initiated by Professor Chung Ik-joo of the College of Medicine for the establishment of an Immunotherapy Innovation Center, which aims to develop a full-cycled immunotherapy innovation platform encompassing the development of anti-cancer immunotherapy source technology, clinical and interventional research and commercialization, which is drawing attention as a new alternative to cancer treatment. The platform's goal is to develop and commercialize innovative immunotherapeutics for cancer and various incurable diseases.

This project was the largest of its kind in Korea in the field of immunological research, in which a total of 46 billion KRW (23 billion KRW from the governmental budget and 23 billion KRW from the local government) will be invested for 5 years. The project was successfully formed with the active support of CNU, Jeollanam-do, and Hwasun County. Through this project, the Immunotherapy Innovation Center will be established in 2021 on the site of the CNU College of Medicine at the CNU Hwasun Campus and gather excellent faculty from CNU and CNU Hwasun Hospital for reaching its goal for ‘open innovation’ for the successful development and commercialization of innovative immunotherapy methods. The project also aims to recruit researchers and experts in immunotherapy from Korea's leading institutes, such as Gwangju Institute of Science and Technology, the Pohang University of Science and Technology, and the Samsung Seoul Hospital, in addition to representative domestic biotech companies specializing in immunotherapy research and development, such as Park Cell Bio Inc., and Pamicell Inc., Selecxin Inc., and SL Vaxigen, Inc.